{"id":"W3083259192","doi":"10.3747/co.27.5459","title":"A Cost–Utility Analysis of Atezolizumab in the Second-Line Treatment of Patients with Metastatic Bladder Cancer","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Public Health Ontario; University of Toronto; University Health Network; Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Canadian Cancer Society Research Institute; Canadian Centre for Applied Research in Cancer Control","keywords":"Atezolizumab; Medicine; Population; Oncology; Cost-effectiveness analysis; Quality-adjusted life year; Cost–benefit analysis; Quality of life (healthcare); Internal medicine; Chemotherapy; Bladder cancer; Intensive care medicine; Cost effectiveness; Cancer; Immunotherapy; Environmental health; Pembrolizumab; Risk analysis (engineering)","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005613565,0.001515556,0.001564288,0.0021081,0.0004645142,0.001942143,0.001464887,0.001275396,0.003727824],"category_scores_gemma":[0.01752763,0.0007191484,0.003872377,0.00179971,0.0006087547,0.0009859425,0.001070009,0.001687272,0.000175637],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01421585,"about_ca_system_score_gemma":0.008540078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1382969,"about_ca_topic_score_gemma":0.0770302,"domain_scores_codex":[0.9973812,0.001766702,0.00008008275,0.0001816155,0.0002991962,0.0002912147],"domain_scores_gemma":[0.9923307,0.006176192,0.0004000766,0.0001401288,0.0006345802,0.0003183222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.003751844,0.0003270418,0.01119693,0.0006726432,0.001482585,0.0004367084,0.00006721968,0.9571528,0.0004524696,0.006387941,0.001866444,0.01620542],"study_design_scores_gemma":[0.0009994599,0.001678488,0.01177721,0.0003284216,0.001970915,0.0003416806,0.0002227811,0.9759999,0.0003457076,0.004179402,0.002075998,0.00007997146],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9276591,0.01098733,0.02558612,0.004147668,0.0001520762,0.001946507,0.01183663,0.0001071218,0.01757743],"genre_scores_gemma":[0.9923103,0.0009641226,0.00395704,0.0001626689,0.00002008332,0.0002366566,0.001447504,0.000009954962,0.000891686],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1382969,"threshold_uncertainty_score":0.2749838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1898816300761954,"score_gpt":0.4304605137584689,"score_spread":0.2405788836822735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}